Esperion Therapeutics Inc.

ESPR

Get informed when a big investor buys or sells

Market Cap$661.15M

Close$

Compare to Similar Companies

	P/E Ratio	Dividends	Return on Equity	Price-to-Sales	Debt-to-Equity
Esperion Therapeutics Inc.	-131.4	99.37%	0%	3.2	-1

$3.19

Target Price by Analysts

0.3% upsideEsperion Therapeutics Target Price Details

$11.14

Current Fair Value

250.2% upside

Undervalued by 250.2% based on the discounted cash flow analysis.

Share Statistics

Market cap	$661.15 Million
Enterprise Value	$801.15 Million
Dividend Yield	$3.16 (99.37%)
Earnings per Share	$-0.11
Beta	1.06
Outstanding Shares	251,353,086

Return

Return on Equity	-0.17%
Return on Assets	0.11%
Return on Invested Capital	47.14%

Valuation & Multiples

P/E Ratio	-131.4
PEG	348.38
Price to Sales	3.18
Price to Book Ratio	-1.59
Enterprise Value to Revenue	1.92
Enterprise Value to EBIT	10.48
Enterprise Value to Net Income	1567
Total Debt to Enterprise	0.37
Debt to Equity	-0.96

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date

August 4, 2026

EPS Estimate

$-0.02

Average shareholder expectation

Revenue Estimate

$92.48 M

Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio	1.2686▲ 100.93%
Total Calls	826,900▼ 74.85%
Total Puts	1,049,000▲ 23.05%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %	80.92%▼ 3.18%
Total Invested	$644.42M▲ 34.50%
Investors Holding	203▼ 16.00%

ESG Score